1. Signaling Pathways
  2. Apoptosis
  3. Apoptosis

Apoptosis

Apoptosis

Apoptosis is a distinctive form of cell death exhibiting specific morphological and biochemical characteristics, including cell membrane blebbing, chromatin condensation, genomic DNA fragmentation, and exposure of specific phagocytosis signaling molecules on the cell surface. Cells undergoing apoptosis differ from those dying through necrosis. Necrotic cells are usually recognized by the immune system as a danger signal and, thus, resulting in inflammation; in contrast, apoptotic death is quiet and orderly.

There are two major pathways of apoptotic cell death induction: The intrinsic pathway, also called the Bcl-2-regulated or mitochondrial pathway, is activated by various developmental cues or cytotoxic insults, such as viral infection, DNA damage and growth-factor deprivation, and is strictly controlled by the BCL-2 family of proteins. The extrinsic or death-receptor pathway is triggered by ligation of death receptors (members of the tumor necrosis factor (TNF) receptor family, such as Fas or TNF receptor-1 (TNFR1)) that contain an intracellular death domain, which can recruit and activate caspase-8 through the adaptor protein Fas-associated death domain (FADD; also known as MORT1) at the cell surface. This recruitment causes subsequent activation of downstream (effector) caspases, such as caspase-3, -6 or -7, without any involvement of the BCL-2 family.

Studies suggest that alterations in cell survival contribute to the pathogenesis of a number of human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome). Treatments designed to specifically alter the apoptotic threshold may have the potential to change the natural progression of some of these diseases.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N6077
    Thalidezine
    Inducer
    Thalidezine is a novel activator of AMP-activated protein kinase (AMPK). Thalidezine can eliminate anti-apoptotic cancer cells through energy-mediated autophagy death. Thalidezine can be used to study apoptosis intervention .
    Thalidezine
  • HY-162752
    Anticancer agent 250
    Anticancer agent 250 (compound 104) has antitumor activity, inducing apoptosis, slowing proliferation, and degrading key oncogenic proteins (such as aRaf, CDK4 ) without inducing a heat shock response.
    Anticancer agent 250
  • HY-B2171
    Carubicin
    Inducer
    Carubicin (Carminomycin) is a microbially-derived compound. Carubicin is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin has the potential for the research of cancer diseases.
    Carubicin
  • HY-150048
    BK50164
    Inducer
    BK50164 is a potent CD73 inhibitor with an IC50 value of 13.089 μM. BK50164 binds to CD99 with a KD value of 1.5 μM. BK50164 shows antiproliferative activity. BK50164 induced Apoptosis and cell cycle arrest at Sub-G1 phase.
    BK50164
  • HY-157749
    Thalidomide-piperazine-(S)-CH2-pyrrolidine-C2-O-CH2-COO-C(CH3)3
    Inducer
    Thalidomide-piperazine-(S)-CH2-Pyrrolidine-C2-O-CH2-COO-C (CH3)3 is a synthetic E3 ligase ligand-Linker conjugate. Thalidomide-piperazine-(S)-Ch2-Pyrrolidine-C2-O-CH2-COO-C(CH3)3 includes Thalidomide-based cereblon ligands and linkers. Thalidomide-piperazine-(S)-CH2-Pyrrolidine-C2-O-CH2-COO-C(CH3)3 can be used to synthesize PROTAC BET.
    Thalidomide-piperazine-(S)-CH2-pyrrolidine-C2-O-CH2-COO-C(CH3)3
  • HY-N1435R
    Oroxin B (Standard)
    Inducer
    Oroxin B (Standard) is the analytical standard of Oroxin B. This product is intended for research and analytical applications. Oroxin B (OB) is a flavonoid isolated from traditional Chinese herbal medicine Oroxylum indicum (L.) Vent. Oroxin B (OB) possesses obvious inhibitory effect and induces early apoptosis rather than late apoptosis on liver cancer cells through upregulation of PTEN, down regulation of COX-2, VEGF, PI3K, and p-AKT. Oroxin B (OB) selectively induces tumor-suppressive ER stress in malignant lymphoma cells.
    Oroxin B (Standard)
  • HY-N1446S4
    Oleic acid-13C-1
    Inducer 99.9%
    Oleic acid-13C-1 is the 13C labeled Oleic acid (HY-N1446). Oleic acid (9-cis-Octadecenoic acid) is an abundant monounsaturated fatty acid. Oleic acid is a Na+/K+ ATPase activator.
    Oleic acid-<sup>13</sup>C-1
  • HY-147833
    ALK-IN-22
    Inducer
    ALK-IN-22 (compound I-24) is a potent ALK inhibitor with IC50 values of 2.3, 3.7 and 2.9 nM for ALK, ALKL1196M and ALKG1202R, respectively. ALK-IN-22 down-regulated the phosphorylation of ALK and its downstream proteins. ALK-IN-22 induces apoptosis. ALK-IN-22 can be used for tumor research.
    ALK-IN-22
  • HY-N6746R
    Citrinin (Standard)
    Inducer
    Citrinin (Standard) is the analytical standard of Citrinin. This product is intended for research and analytical applications. Citrinin (NSC 186) is a mycotoxin that causes food contamination and has different toxic effects. Citrinin is an effective oral anticancer agent. Citrinin has various regulatory effects on mouse immune system, including regulating the number of immune cells, inducing apoptosis and autophagy of immune cells, altering toll-like receptor expression and cytokine production. Citrinin can induce oxidative stress and lead to early apoptosis of oocytes. Low doses of Citrinin have neuroprotective effects against glutamate-induced excitotoxicity in rat cortical neurons. In addition, Citrinin also has antibacterial activity.
    Citrinin (Standard)
  • HY-N3561
    Cedrelone
    Inducer
    Cedrelone, a limonoid, is a Phenazine biosynthesis-like domain-containing protein (PBLD) activator. Cedrelone induces cancer cell apoptosis, and possess antitumor effects.
    Cedrelone
  • HY-P5754
    TAT-NEP1-40
    Inhibitor
    TAT-NEP1-40 is a BBB-penatrable peptide. TAT-NEP1-40 protects PC12 cells against oxygen and glucose deprivation (OGD), and promotes neurite outgrowth. TAT-NEP1-40 also improves ischemia-induced neurologic outcomes by inhibiting cell apoptosis in ischemic brains. TAT-NEP1-40 can be used for research of CNS injuries, such as axonal regeneration and functional recovery after stroke.
    TAT-NEP1-40
  • HY-158138
    TOPOI/PARP-1-IN-1
    Inducer
    TOPOI/PARP-1-IN-1 (Compound B6) is an orally active, low cytotoxic TOPOI/PARP dual inhibitor with an IC50 value of 0.09 μM for PARP1. TOPOI/PARP-1-IN-1 can effectively inhibit the proliferation and migration of cancer cells. TOPOI/PARP-1-IN-1 also causes cell cycle arrest in the G0/G1 phase and induces apoptosis. The tumor growth inhibition rate (TGI) of TOPOI/PARP-1-IN-1 in mice is 75.4%.
    TOPOI/PARP-1-IN-1
  • HY-179161
    CDK2-IN-49
    Inducer
    CDK2-IN-49 (Compound 5j) is a CDK2 inhibitor with an IC50 of 0.25 μM. CDK2-IN-49 shows potent activity against CDK7 with an IC50 of 0.14 μM. CDK2-IN-49 induces Apoptosis by raising the levels of p53 and Bax protein expression while reducing the amount of Bcl-2. CDK2-IN-49 inhibits cell division. CDK2-IN-49 can be used in the research of cancer.
    CDK2-IN-49
  • HY-151153
    HDAC1-IN-5
    Inducer
    HDAC1-IN-5 is a potent HDAC1 inhibitor with IC50 values of 15 nM and 20 nM for HDAC1 and HDAC6, respectively. HDAC1-IN-5 can enhance the acetylation of histone H3 and α-tubulin, as well as promote the activation of caspase 3 in cancer cells, thereby inducing apoptosis. HDAC1-IN-5 induces chromatin damage by binding with DNA. HDAC1-IN-5 has strong inhibitory activity against tumor growth in xenograft mice.
    HDAC1-IN-5
  • HY-B0689B
    Indinavir sulfate ethanolate
    Inducer
    Indinavir sulfate ethanolate (MK-639 ethanolate) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate ethanolate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate ethanolate is also a SARS-CoV 3CLpro inhibitor.
    Indinavir sulfate ethanolate
  • HY-111027
    HDAC8-IN-13
    HDAC8-IN-13 is a novel histone deacetylase 8 (HDAC8) inhibitor with antiparasitic activity. HDAC8-IN-13 can effectively inhibit the acetyl-L-lysine deacetylase activity of schistosomes, affecting the parasite's infectivity. HDAC8-IN-13 can induce apoptosis and cause the death of schistosome cells. Through a specific structural basis design, HDAC8-IN-13 exhibits reduced affinity for human HDACs, thereby enhancing its selectivity.
    HDAC8-IN-13
  • HY-154960
    Tubulin/AKT1-IN-1
    Inducer
    Tubulin/AKT1-IN-1 (Compound D1-1) is an inhibitor of tubulin polymerization and AKT pathway activation. Tubulin/AKT1-IN-1 significantly inhibits the proliferation and metastasis of H1975 cells and slightly induced their apoptosis and can be used for non-small-cell lung cancer (NSCLC) research .
    Tubulin/AKT1-IN-1
  • HY-17595S1
    Mebendazole-d8
    Inducer
    Mebendazole-d8 is the deuterium labeled Mebendazole. Mebendazole is a highly effective, broad-spectrum antihelmintic indicated for the treatment of nematode infestations; has been found as a hedgehog inhibitor.
    Mebendazole-d<sub>8</sub>
  • HY-175057
    Ac-IETD-CHO TFA
    Inhibitor
    Ac-IETD-CHO TFA is a potent, reversible inhibitor of granzyme B and caspase-8. Ac-IETD-CHO TFA inhibits Fas-mediated apoptotic cell death, hemorrhage, and liver failure. Ac-IETD-CHO TFA also inhibits cytotoxic T lymphocytes induced cell death.
    Ac-IETD-CHO TFA
  • HY-175853
    Topoisomerase II-IN-24
    Inducer
    Topoisomerase II-IN-24 is a Topoisomerase IIα inhibitor with an IC50 of 41.67 μM. Topoisomerase II-IN-24 can inhibit cancer cells proliferation, induce G2/M phase arrest and induce apoptosis. Topoisomerase II-IN-24 can be used for the research of cancer, such as colon cancer.
    Topoisomerase II-IN-24
Cat. No. Product Name / Synonyms Application Reactivity